How and when to apply GMPs to early-phase therapeutic drug substances is a challenging proposition. PDA Technical Report No. 56 provides answers and guidance to those dealing with the challenge. The report covers phase-appropriate CGMPs during the manufacturing of therapeutic protein drug substance (biological active substance) from the R&D stage through completion of phase 3 clinical trials. The scope also includes implementation of a pharmaceutical quality system that ensures the safety and quality of products intended for use in clinical trials. Finally, it provides the basis for subsequent assurance of the equivalence of products used in trials to products submitted for marketing approval. This report will focus on current best practices.
This is the second Technical Report released under PDA's Paradigm Change in Manufacturing Operations SM (PCMOSM).
Available to download
Format: PDF (1 file 607 KB)
Click here to view the digital downloading instruction and Terms of Usage
*To purchase licensing, please contact PDA at email@example.com.